In this international , randomised , controlled , double-blind , phase 3 , non-inferiority with nested superiority trial , adult Asian patients with Pneumonia Outcomes Research Team ( PORT ) risk class III-IV acute community-acquired pneumonia were randomly assigned ( 1:1 ) to receive intravenous ceftaroline fosamil ( 600 mg every 12 h ) or ceftriaxone ( 2 g every 24 h ) for 5-7 days .